24 Hour Ambulatory Cardiac Oxygen Consumption

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized,double-blind,double-dummy,active controlled,15 week study to evaluate the effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac work and variability of heart rate-mean central systolic pressure product.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: State University of New York at Buffalo
• Treatments: Nebivolol; Valsartan

Criteria

Inclusion Criteria:

• Subjects with chronic hypertension, treated or untreated

• Males and females, 18 years or older

• Seated clinic systolic BP 145-184 mmHg inclusive or

• Seated clinic diastolic BP 92-119 mmHg, inclusive.

Exclusion Criteria:

• Subjects with any of the following conditions will be excluded:

• Any acute or chronic medical condition that, in the judgment of the investigator, renders the subject unable to complete the study, would interfere with optimal participation in the study, or cause significant risk to the subject

• Concomitant or probable need for treatment with other cardiovascular or antihypertensive drugs that may affect blood pressure or influence the effects of study drugs, (e.g. NSAIDs, beta-agonist inhalers therapy for bronchospastic asthma, diuretics); other stable chronic medications that have little effect on study drugs (e.g. diabetes medications, hormone replacements, chronic pain medications. osteoporosis drugs, vitamins, cholesterol drugs, etc.) are permitted if continued at stable doses throughout study.

• History of clinically significant adverse events with beta-blocker or angiotensin-receptor blocker

• Known or suspected secondary hypertension (e.g., renovascular hypertension, primary hyperaldosteronism, etc.)

• Known ischemic heart disease requiring continuous beta-blocker therapy (includes angina, prior transmural myocardial infarction, coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty or stenting within 6 months prior to study entry).

• Dilated cardiomyopathy (NYHA Functional Class III-IV)

• Clinically significant valvular heart disease or obstructive hypertrophic cardiomyopathy

• Presence of clinically significant ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter), pre-excitation syndrome, second or third degree atrioventricular block, other conduction defects necessitating the implantation of a permanent cardiac pacemaker, or sick sinus syndrome.

• Chronic kidney disease (serum creatinine >2.5 mg/dL)

• Uncontrolled diabetes mellitus (hemoglobin A1c > 10%)

• History of alcohol or other drug abuse within 6 months prior to enrollment

• Positive pregnancy test or failure to practice adequate contraception in women of child-bearing potential